Fewer than 3% of US sickle cell disease patients receive red blood cell exchange therapy, despite 91% of surveyed healthcare providers having access to the treatment. Experts point to departmental coordination hurdles, blood supply limits, and insurance coverage gaps as major obstacles to care.
A new nationally representative survey of 100 US-based healthcare providers who actively manage at least one patient with sickle cell disease reveals a stark gap in modern treatment access. While 91% of surveyed clinicians report having access to red blood cell exchange technology, fewer than 3% of patients have actually received the procedure.
Barriers to Care Across US Medical Centers
The procedure in question discards a patient’s damaged red blood cells while simultaneously mixing the remaining plasma, platelets, and white blood cells with donor red blood cells before returning them to the body. Despite the availability of this technology, providers face multiple roadblocks in administering it according to the research.
Survey data shows that only a minority of healthcare providers surveyed had no barriers when attempting to deliver the treatment. The most common challenges include coordinating care between different medical departments, maintaining an adequate supply of donated blood, and a general lack of familiarity with the procedure among medical staff. Patients frequently worry about whether health insurance will cover red blood cell exchange therapy.
Demographics and Geographic Disparities in Sickle Cell Disease
Sickle cell disease is an inherited disorder affecting hemoglobin, the protein that carries oxygen in red blood cells. Normal red blood cells are disc-shaped and flexible, allowing them to pass easily through blood vessels, whereas affected individuals produce crescent- or sickle-shaped cells that can block blood flow, as outlined by the National Heart, Lung, and Blood Institute.
The condition affects more than 100,000 people across the United States and 8 million people worldwide, disproportionately impacting communities of color. Non-Hispanic Black or African Americans account for 90% of those diagnosed, while Hispanic or Latino individuals represent an estimated 3% to 9%.
“A lot of sickle cell patients live in rural areas and so only have access to rural hospitals. If you look at the distribution of sickle cell disease, it primarily affects African Americans who tend to be in states in the south that can be more rural, and so have less access to some of these equipment.”
Dr Edward Donnell Ivy, Sickle Cell Disease Association of America
Dr Edward Donnell Ivy, chief medical officer at the Sickle Cell Disease Association of America, noted that roughly 80% of sickle cell patients are enrolled in Medicaid and face significant socioeconomic vulnerabilities. Ivy also pointed out that patients themselves sometimes lack awareness to ask about advanced therapies, compounded by a general shortage of providers who fully understand how to manage the disease and its risk factors.
The Role of Comprehensive Centers and Specialized Donors
Dr Aaron Haubner of the University of Kentucky College of Pharmacy, lead author of the research, described new therapies as exciting but ultimately out of reach for most patients.
“Patients with sickle cell disease benefit from coordinated access to hematologists, transfusion and apheresis specialists, nurse educators, care coordinators, and other support services. In many communities – outside of dedicated centers of excellence – these resources simply aren’t available.”
Dr Aaron Haubner, University of Kentucky College of Pharmacy
To address these gaps, local blood collection agencies are stepping up awareness campaigns. In Greater Cincinnati, where more than 350 people live with sickle cell disease, the Hoxworth Blood Center at the University of Cincinnati is urging eligible residents to donate blood. Because regular transfusions require closely matched blood, donors of African descent are particularly vital due to shared red blood cell characteristics.
Dr Shannon Kelly, medical director of the apheresis program at UCSF Benioff Children’s Hospital Oakland, emphasized that even large medical institutions frequently lack dedicated apheresis programs capable of providing automated red blood cell exchange, leading to frequent patient transfers.
Keep reading